diabetes management
Dexcom G6 users will now be able to integrate their continuous glucose monitor to the Livongo platform for more personalized insights and coaching.
The clearance of Tandem Diabetes Care’s Control-IQ Technology opens the door for new algorithms enabling hybrid closed-loop diabetes management systems.
New CEO Paul Hudson said during today's strategy presentation that the company had "over-invested" in the joint venture back in 2016.
While Dexcom reports that interruptions in the service are mostly under control, many customers are critiquing the company's poor messaging of the issue, which they say could be fatal.
The announcement comes not long after competitor One Drop began rolling out its similar offering in Apple Stores and Walmarts.
Astellas will be paying Welldoc $15 million up front for certain rights to the diabetes digital therapeutic, and will also be on the hook for milestones and royalty payments.
A study being presented this weekend in Philadelphia is the latest data on Livongo's programs, which combine connected monitoring devices and digital coaching.
This is the seventh FDA clearance for the longstanding mobile diabetes management platform.
All of the life insurer’s members with Type 1 or Type 2 diabetes will have access to the service, which offers savings on premiums.
Integrating Fitbit into the platform provides Health2Sync users with a more holistic view of their health, which can support them in making healthy lifestyle choices to better manage their condition.